Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
47
MEPDF Quote, Financials, Valuation and Earnings
Last price:
$16.50
Seasonality move
:
2.46%
Day range:
$16.50 - $16.50
52-week range:
$13.24 - $17.57
Dividend yield:
2.59%
P/E ratio:
12.54x
P/S ratio:
0.14x
P/B ratio:
0.80x
Volume:
--
Avg. volume:
--
1-year change:
24.62%
Market cap:
$3.4B
Revenue:
$24.1B
EPS (TTM):
$1.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MEPDF
Medipal Holdings Corp.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MEPDF
Medipal Holdings Corp.
|
$16.50 | -- | $3.4B | 12.54x | $0.21 | 2.59% | 0.14x |
|
HLOSF
Healios KK
|
$1.93 | -- | $222.8M | -- | $0.00 | 0% | 303.04x |
|
PPTDF
PeptiDream Inc.
|
$11.98 | -- | $1.5B | 13.79x | $0.00 | 0% | 12.90x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.08 | -- | $459.3M | -- | $0.00 | 0% | 2.37x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.46 | $17.93 | $48.8B | 196.19x | $0.32 | 4.28% | 1.66x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MEPDF
Medipal Holdings Corp.
|
5.95% | -0.262 | 6.32% | 1.00x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MEPDF
Medipal Holdings Corp.
|
$422M | $74.8M | 6.45% | 6.73% | 1.16% | -- |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Medipal Holdings Corp. vs. Competitors
-
Which has Higher Returns MEPDF or HLOSF?
Healios KK has a net margin of 1.56% compared to Medipal Holdings Corp.'s net margin of -9751.87%. Medipal Holdings Corp.'s return on equity of 6.73% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital MEPDFMedipal Holdings Corp.6.53% $0.41 $5.5B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About MEPDF or HLOSF?
Medipal Holdings Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Medipal Holdings Corp. has higher upside potential than Healios KK, analysts believe Medipal Holdings Corp. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings MEPDFMedipal Holdings Corp.0 0 0 HLOSFHealios KK0 0 0 -
Is MEPDF or HLOSF More Risky?
Medipal Holdings Corp. has a beta of 0.358, which suggesting that the stock is 64.165% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock MEPDF or HLOSF?
Medipal Holdings Corp. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.59%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medipal Holdings Corp. pays 32.09% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Medipal Holdings Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MEPDF or HLOSF?
Medipal Holdings Corp. quarterly revenues are $6.5B, which are larger than Healios KK quarterly revenues of $128.8K. Medipal Holdings Corp.'s net income of $100.9M is higher than Healios KK's net income of $3.8M. Notably, Medipal Holdings Corp.'s price-to-earnings ratio is 12.54x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medipal Holdings Corp. is 0.14x versus 303.04x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEPDFMedipal Holdings Corp.0.14x 12.54x $6.5B $100.9M HLOSFHealios KK303.04x -- $128.8K $3.8M
-
Which has Higher Returns MEPDF or PPTDF?
PeptiDream Inc. has a net margin of 1.56% compared to Medipal Holdings Corp.'s net margin of -25.38%. Medipal Holdings Corp.'s return on equity of 6.73% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital MEPDFMedipal Holdings Corp.6.53% $0.41 $5.5B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About MEPDF or PPTDF?
Medipal Holdings Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medipal Holdings Corp. has higher upside potential than PeptiDream Inc., analysts believe Medipal Holdings Corp. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings MEPDFMedipal Holdings Corp.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is MEPDF or PPTDF More Risky?
Medipal Holdings Corp. has a beta of 0.358, which suggesting that the stock is 64.165% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock MEPDF or PPTDF?
Medipal Holdings Corp. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.59%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medipal Holdings Corp. pays 32.09% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Medipal Holdings Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MEPDF or PPTDF?
Medipal Holdings Corp. quarterly revenues are $6.5B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Medipal Holdings Corp.'s net income of $100.9M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Medipal Holdings Corp.'s price-to-earnings ratio is 12.54x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medipal Holdings Corp. is 0.14x versus 12.90x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEPDFMedipal Holdings Corp.0.14x 12.54x $6.5B $100.9M PPTDFPeptiDream Inc.12.90x 13.79x $29.3M -$7.4M
-
Which has Higher Returns MEPDF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 1.56% compared to Medipal Holdings Corp.'s net margin of -24.76%. Medipal Holdings Corp.'s return on equity of 6.73% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital MEPDFMedipal Holdings Corp.6.53% $0.41 $5.5B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About MEPDF or SOLTF?
Medipal Holdings Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medipal Holdings Corp. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Medipal Holdings Corp. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MEPDFMedipal Holdings Corp.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is MEPDF or SOLTF More Risky?
Medipal Holdings Corp. has a beta of 0.358, which suggesting that the stock is 64.165% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock MEPDF or SOLTF?
Medipal Holdings Corp. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.59%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medipal Holdings Corp. pays 32.09% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Medipal Holdings Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MEPDF or SOLTF?
Medipal Holdings Corp. quarterly revenues are $6.5B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Medipal Holdings Corp.'s net income of $100.9M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Medipal Holdings Corp.'s price-to-earnings ratio is 12.54x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medipal Holdings Corp. is 0.14x versus 2.37x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEPDFMedipal Holdings Corp.0.14x 12.54x $6.5B $100.9M SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M
-
Which has Higher Returns MEPDF or STMM?
Stemcell Holdings, Inc. has a net margin of 1.56% compared to Medipal Holdings Corp.'s net margin of --. Medipal Holdings Corp.'s return on equity of 6.73% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEPDFMedipal Holdings Corp.6.53% $0.41 $5.5B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About MEPDF or STMM?
Medipal Holdings Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medipal Holdings Corp. has higher upside potential than Stemcell Holdings, Inc., analysts believe Medipal Holdings Corp. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MEPDFMedipal Holdings Corp.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is MEPDF or STMM More Risky?
Medipal Holdings Corp. has a beta of 0.358, which suggesting that the stock is 64.165% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MEPDF or STMM?
Medipal Holdings Corp. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.59%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medipal Holdings Corp. pays 32.09% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Medipal Holdings Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MEPDF or STMM?
Medipal Holdings Corp. quarterly revenues are $6.5B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Medipal Holdings Corp.'s net income of $100.9M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Medipal Holdings Corp.'s price-to-earnings ratio is 12.54x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medipal Holdings Corp. is 0.14x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEPDFMedipal Holdings Corp.0.14x 12.54x $6.5B $100.9M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns MEPDF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 1.56% compared to Medipal Holdings Corp.'s net margin of -1.05%. Medipal Holdings Corp.'s return on equity of 6.73% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital MEPDFMedipal Holdings Corp.6.53% $0.41 $5.5B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About MEPDF or TAK?
Medipal Holdings Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 15.83%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Medipal Holdings Corp., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Medipal Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings MEPDFMedipal Holdings Corp.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is MEPDF or TAK More Risky?
Medipal Holdings Corp. has a beta of 0.358, which suggesting that the stock is 64.165% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock MEPDF or TAK?
Medipal Holdings Corp. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.59%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.28% to investors and pays a quarterly dividend of $0.32 per share. Medipal Holdings Corp. pays 32.09% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Medipal Holdings Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios MEPDF or TAK?
Medipal Holdings Corp. quarterly revenues are $6.5B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Medipal Holdings Corp.'s net income of $100.9M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Medipal Holdings Corp.'s price-to-earnings ratio is 12.54x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 196.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medipal Holdings Corp. is 0.14x versus 1.66x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEPDFMedipal Holdings Corp.0.14x 12.54x $6.5B $100.9M TAKTakeda Pharmaceutical Co., Ltd.1.66x 196.19x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 4.87% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.49% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 1.53% over the past day.
